Scarica l'app Stockscreener
49.00
1.03%
-0.51
Dopo l'orario di chiusura:
49.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$49.51
Aprire:
$49.39
Volume 24 ore:
1.05M
Relative Volume:
1.28
Capitalizzazione di mercato:
$2.75B
Reddito:
$651.97M
Utile/perdita netta:
$59.71M
Rapporto P/E:
45.81
EPS:
1.0696
Flusso di cassa netto:
$172.03M
1 W Prestazione:
+1.34%
1M Prestazione:
+6.04%
6M Prestazione:
+57.71%
1 anno Prestazione:
+53.65%
Intervallo 1D:
$48.27
$49.81
Intervallo di 1 settimana:
$47.27
$51.78
Portata 52W:
$29.16
$51.78
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
49.00 | 2.78B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Supernus Pharmaceuticals Shares Rise After Piper Sandler Upgrade - MarketScreener
Supernus Pharmaceuticals: A Rising Pharma Contender? - StocksToTrade
Supernus Pharmaceuticals (SUPN) Stock Is Up, What You Need To Know - TradingView
SUPN: Piper Sandler Raises Price Target to $65 and Upgrades Rati - GuruFocus
Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $65 From $40 - MarketScreener
Can Supernus Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Big Picture & Weekly Market Pulse Updates - newser.com
How Supernus Pharmaceuticals Inc. stock performs during Fed tightening cycles2025 Market Outlook & Fast Exit and Entry Strategy Plans - newser.com
Published on: 2025-10-09 05:01:01 - newser.com
Supernus (SUPN) Receives Upgraded Rating Amid Promising Product Outlook - GuruFocus
How to use Fibonacci retracement on Supernus Pharmaceuticals Inc.2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Is now a turning point for Supernus Pharmaceuticals Inc.July 2025 Earnings & Real-Time Sentiment Analysis - newser.com
Supernus Pharmaceuticals Hits New 52-Week High of $49.66 - Markets Mojo
Will Supernus Pharmaceuticals Inc. rebound enough to break evenDollar Strength & Weekly Top Performers Watchlists - newser.com
How geopolitical tensions affect Supernus Pharmaceuticals Inc. stockCPI Data & Comprehensive Market Scan Insights - newser.com
Why Supernus Pharmaceuticals Inc. stock could be next big winnerJuly 2025 Decliners & Community Trade Idea Sharing Platform - newser.com
Using R and stats models for Supernus Pharmaceuticals Inc. forecasting2025 Macro Impact & Reliable Volume Spike Trade Alerts - newser.com
Is Supernus Pharmaceuticals Inc. stock poised for growthPortfolio Growth Summary & Real-Time Market Trend Scan - newser.com
Is Supernus Pharmaceuticals Inc. stock cheap compared to fundamentalsAnalyst Upgrade & Daily Stock Trend Reports - newser.com
Wall Street Zen Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Hold - Defense World
Smart tools for monitoring Supernus Pharmaceuticals Inc.’s price actionQuarterly Portfolio Review & High Conviction Buy Zone Alerts - newser.com
Real time social sentiment graph for Supernus Pharmaceuticals Inc.Trade Volume Summary & Real-Time Buy Zone Alerts - newser.com
Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by GAMMA Investing LLC - Defense World
What MACD signals say about Supernus Pharmaceuticals Inc.Market Volume Summary & Low Drawdown Momentum Trade Ideas - newser.com
Supernus Pharmaceuticals stock hits 52-week high at 48.47 USD - Investing.com India
Supernus Pharmaceuticals stock hits 52-week high at 48.47 USD By Investing.com - Investing.com Australia
Supernus Pharmaceuticals (SUPN): Is the Current Share Price a Fair Reflection of Its True Valuation? - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 18% CAGR over the last five years - simplywall.st
Supernus Pharmaceuticals (NASDAQ:SUPN) Given New $63.00 Price Target at Cantor Fitzgerald - Defense World
Supernus Pharmaceuticals Hits New 52-Week High of $48.00 - Markets Mojo
SUPN: Cantor Fitzgerald Increases Price Target to $63, Maintains Overweight Rating | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
1.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):